Connect
We built Decide, the most complete connected picture of this industry that exists, and we use every modern tool — AI included — wherever it earns its place. We are not sentimental about technology.
What the tools don’t do is decide what’s worth tracking, how a market should be defined, or which question you’re really asking underneath the one you asked.

What we do
Strategic, high-level and downstream: operations, supply chain, marketing and sales.
Market
Where is the volume actually going, at what price, and who is taking it? We size the market from customs records, dispensing data and company accounts — then show you the denominator behind every figure so your board can interrogate it.
Strategy
Entry sequencing, pricing corridors, partner shortlists and the case you put in front of an investment committee. We have watched this industry make the same mistakes twice, which is the most useful thing we can bring to a plan.
Data
When the answer is not published anywhere, we build the dataset: surveys, structured interviews, freedom-of-information requests, retailer fieldwork, and parsing public records nobody has cleaned. It is the half of the job most firms skip.
Regulation
What a decree will actually do to a P&L, which licence class you need, where the bottleneck sits between legal-on-paper and available-in-pharmacy — and how long the gap has taken to close in comparable markets.
We don’t work directly on scientific affairs, quality and compliance, or agronomy and production engagements.
How we work
Almost every firm in this sector reads the news and forms a view. We start one layer down: we build and own the underlying dataset, and the advice is what falls out of it. Four things follow, and each one is easier to show than to describe.
Regulator filings, customs records, dispensing data and company accounts at the top. Industry surveys and trade estimates below. Press reporting is a lead, not a source. When two sources disagree we show you the disagreement and say which we’d trust.
What decides a figure
Which record we publish
Cannabis shipped from Spain to Germany, 2025
For a shipment that crosses a border we publish the importing country’s figure: it is the customs counterparty and answers for the number. Estimates from the exporting side tell us where to look, and are never printed as the record.
Surveys, structured interviews, freedom-of-information requests, retailer fieldwork, and the patient work of parsing records nobody has cleaned. It is how the UK market became measurable at all.
Records behind our datasets
One cannabis-specific taxonomy across 120 markets, maintained over time — so a figure from Poland in 2024 means the same thing as one from Australia in 2026.
Five markets, one field
The same product, as five markets write it down. In our data it is one value, so a tonne of it compares across all of them.
It runs right through our pipeline: ingestion, classification, translation, first-pass extraction. We would be worse at this without it, and anyone claiming otherwise is either behind or bluffing.
Who does what
Anyone can buy the same models. Nobody can buy eight years of decisions about what the data should be called.
A model can work inside a frame like that at enormous speed. It cannot build the frame, and it cannot tell you when the frame is wrong.
Who we work with
Pick the one closest to you: what we do for it, what our intelligence looks like for that question, and a piece of work we can talk about.
You have a licence application, a thesis and a deck. What you don’t have is a defensible number. We size the opportunity properly, find the value proposition that survives contact with the market, and assemble the research a serious investor will ask for — before you go out.
Tonnes imported per quarter, Q1 2024 – Q1 2026
The Peak Beyond builds interactive displays for dispensaries, and had just run its first advertising pilot: nine brands across 108 smart stations. To sell the idea to brands it needed independent proof. We joined the stations’ click data to the dispensaries’ own sales records and measured the lift: sales of the advertised brands rose 76% once the ads went live.
“Great working with Arnau. We would definitely hire him again.”The Peak Beyond — Cannabis Retail Analytics
You are already licensed and selling. The question is which channel, which product, which country next — and what the numbers say rather than what the trade press says.
% of items · Curaleaf vs the top five operators
Somaí operates at scale near Lisbon, making bulk extracts, APIs and finished products for international medical markets. The question was who, specifically, to sell to. We built a qualified lead directory across API companies and CDMOs — several hundred potential partners, segmented by location, need and activity, and ranked by priority, with an outreach strategy for reaching them.
You run a real business in another industry and cannabis is the adjacency. You need to know the competitive position you are walking into, what determines success here, and which of the received wisdom is wrong.
Pax makes vaporisation devices sold worldwide, and wanted to know how far they had genuinely penetrated European retail — pharmacy, CBD shops, vape shops — across six key markets. There was no dataset for this, so we built one: a European retailer database assembled from CRM records, web-scraping and manual primary research, set against a competitive landscape drawn from the same sources. What came out was a growth roadmap, market by market.
You are pricing an operator, a market or a whole thesis. We give you the independent read — including the parts management would rather you didn’t model.
Cannabis deals per year · 2026 to 5 October
When Germany opened in 2024, Essence Investment wanted to understand the cannabis seed business before committing to it. Spain has had a legal seed market for decades, so we took it apart as the precedent: the market by channel and seed type, the supply chain and its margins, and how the leading brands position themselves — built from company accounts in the commercial registry, retail prices collected seed bank by seed bank, and interviews with the people in the trade.
Ministries, regulators and trade agencies need numbers they can defend in public, produced by someone with no position in the outcome.
Share of export value by destination
Uruguay legalised before anyone else and built real production capacity early. The harder question was where any of it could actually go: which import markets were open, on what terms, to whom, and at what price. We provided export intelligence on international markets for Uruguayan operators — mapping destination markets, their import requirements and the commercial realities behind them. The beneficiary wasn’t one company. It was a national industry.







Career
Education
Political Science, UAB · MA Public Opinion Management, Universitat de València · Postgraduate Data Analytics, UOC
Why I do this
I got into cannabis market data because there were almost no reliable numbers behind the big claims. As a data professional, that looked like a large opportunity.
Ten years in market research taught me what proper data and analytics look like — and how far they can shape operational decisions, strategy and social outcomes.
When I entered the sector in 2018 there was no good data available. Market-sizing claims were enormous and contradictory, “trust me, bro” was the standard of evidence for a trend, and insights had to be scraped from the first-hand experience of operators.
Worse, companies were making expensive decisions on the back of badly defined data. Things have improved since, but there is still a long way to go before emerging cannabinoid markets get the level of data that pharmaceutical and CPG businesses take for granted.
A market that cannot be measured does not attract investment, and a regulator without visibility legislates cautiously, or not at all.
That is Cannamonitor’s vision, and what we work towards every day. Proper data lets operators make the right call ahead of everyone else, and it is a big determinant of who succeeds.
Every market we size properly is one that can be argued about honestly — and industry, patients and consumers stand to gain the most. Cannabis has spent long enough being argued about dishonestly; shortcuts only compound the stigma.
There is a lot worth getting right: cannabinoids in medicine, hemp in food and materials, an industry that employs people and strengthens the economy. None of it happens on numbers nobody trusts — so our commitment is to sound methodology and the highest level of integrity.
Arnau ValdovinosFounder & principal analyst, BarcelonaStage & podcast



Cannabis Data Science
Green Queens2018
The first market-entry mandates into Europe, the year Germany opened
2019
Led the research behind Europe’s first cannabis intelligence platform
Proof
Reported by national press in Spain, the UK and Germany, and across the European and Latin American trade press, continuously since 2024.
















“The report is amazing. Congratulations for being the most loved and hated person in cannabis at the same time.”
Alessandro RossoniCo-founder & CEO, Nimbus Health“It is the best report on the market. The depth, the concise insights, the data visualisation — all of it makes it number one.”
Yerbol KuljanovBD Director, Essence Investment“Cannamonitor is the best source of international cannabis activity out there.”
Ruth Fisher, PhDCo-founder, CannDynamics“This report adds great value to the sector. Many thanks for your dedication and analysis.”
Telmo GüellCEO, The Beemine Lab“The professionalism in the approach was second only to the quality of commercial leads we generated as a result.”
Callum KellasCommercial Intelligence Study“Excellent work. The information provided in the report is of enormous value.”
João DuarteBusiness Development, Decimal EngineeredProducts
Not everything needs a project. Four levels, from a free monthly brief to a bespoke programme.
Collaborate
Pick the one that fits and it carries through to the form, so you don’t have to explain it twice.
A study built around your question — sizing, entry, competitive landscape, pricing, supply chain. Including primary research where the data doesn’t exist yet.
Report · underlying data · a walkthrough session
Start a research briefOngoing analyst access for a board, an investment committee or a strategy team that needs someone to ask.
Monthly · rolling
Request an advisory callOur datasets inside your own systems, reports or product. Multi-seat, API, bespoke taxonomies, white-label.
Annual licence
Talk about licensingCo-authored research, data partnerships, panels, webinars, and expert comment when you’re on deadline.
Tell us what you have in mind
Get in touchStart a conversation
Whatever you send stays between us. We don’t share, sell or pass on enquiry details, and nothing here signs you up to anything.
What happens next
Send it to an analyst
The form is loading. If it doesn’t appear, your browser may be blocking it: write to info@cannamonitor.com and you’ll get the same reply.